Ishihara M

References (4)

Title : Genome analysis of three Pneumocystis species reveals adaptation mechanisms to life exclusively in mammalian hosts - Ma_2016_Nat.Commun_7_10740
Author(s) : Ma L , Chen Z , Huang da W , Kutty G , Ishihara M , Wang H , Abouelleil A , Bishop L , Davey E , Deng R , Deng X , Fan L , Fantoni G , FitzGerald M , Gogineni E , Goldberg JM , Handley G , Hu X , Huber C , Jiao X , Jones K , Levin JZ , Liu Y , Macdonald P , Melnikov A , Raley C , Sassi M , Sherman BT , Song X , Sykes S , Tran B , Walsh L , Xia Y , Yang J , Young S , Zeng Q , Zheng X , Stephens R , Nusbaum C , Birren BW , Azadi P , Lempicki RA , Cuomo CA , Kovacs JA
Ref : Nat Commun , 7 :10740 , 2016
Abstract : Pneumocystis jirovecii is a major cause of life-threatening pneumonia in immunosuppressed patients including transplant recipients and those with HIV/AIDS, yet surprisingly little is known about the biology of this fungal pathogen. Here we report near complete genome assemblies for three Pneumocystis species that infect humans, rats and mice. Pneumocystis genomes are highly compact relative to other fungi, with substantial reductions of ribosomal RNA genes, transporters, transcription factors and many metabolic pathways, but contain expansions of surface proteins, especially a unique and complex surface glycoprotein superfamily, as well as proteases and RNA processing proteins. Unexpectedly, the key fungal cell wall components chitin and outer chain N-mannans are absent, based on genome content and experimental validation. Our findings suggest that Pneumocystis has developed unique mechanisms of adaptation to life exclusively in mammalian hosts, including dependence on the lungs for gas and nutrients and highly efficient strategies to escape both host innate and acquired immune defenses.
ESTHER : Ma_2016_Nat.Commun_7_10740
PubMedSearch : Ma_2016_Nat.Commun_7_10740
PubMedID: 26899007
Gene_locus related to this paper: pnec8-a0a0w4zi95 , pnemu-m7nra0 , pnej8-l0pgn2 , pnemu-m7nsb0

Title : Prospective analysis of primary modified Georgeson's laparoscopy-assisted endorectal pull-through for Hirschsprung's disease: short- to mid-term results - Ishihara_2005_Pediatr.Surg.Int_21_878
Author(s) : Ishihara M , Yamataka A , Kaneyama K , Koga H , Kobayashi H , Lane GJ , Miyano T
Ref : Pediatr Surg Int , 21 :878 , 2005
Abstract : The aim of this study was to analyze the short- to mid-term outcome of primary modified Georgeson's laparoscopy-assisted endorectal pull-through (PMGLEPT) for Hirschsprung's disease (HD). HD patients treated by PMGLEPT were evaluated prospectively by a single surgeon using a standard structured questionnaire to assess complications, incidence of enterocolitis, and evaluate continence (CE). CE involved scoring five parameters (frequency of motions, severity of staining/soiling, severity of perianal erosions, anal shape, and requirement for medications) on a 3-point scale (0, 1, and 2 for each parameter). Thus, scores for CE were: 10 = normal, 8-9 = good, 6-7 = fair, and 0-5 = poor. Our modifications include transanal rectal dissection starting below or on the dentate line, near total excision of the posterior rectal cuff, and intraoperative acetylcholinesterase staining to accurately identify normal colon. Patients with total colon aganglionosis or trisomy-21 were excluded, leaving 33 cases of PMGLEPT performed between 1997 and 2004. Mean operative age was 11.0 months. Follow-up ranged from 8 months to 7 years (mean 4.0 years). There were no intraoperative complications. Post-PMGLEP, bowel obstruction occurred in 1 subject who required middle colic division for pull-through (PT), and enterocolitis occurred in 3 (9.1%) of 33 patients. In 20 subjects aged over 3 years with a follow-up period of more than 12 months, final CE was normal in 5, good in 10, fair in 4, and poor in 1, despite staining/soiling being present in 12 (60%) of 20 subjects. None of the 33 had constipation. Our results suggest that PMGLEPT is safe with acceptable outcome in the short- to mid-term. However, careful long-term follow-up is mandatory as there appears to be a relatively high incidence of staining/soiling on short- to mid-term follow-up.
ESTHER : Ishihara_2005_Pediatr.Surg.Int_21_878
PubMedSearch : Ishihara_2005_Pediatr.Surg.Int_21_878
PubMedID: 16133514

Title : Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients - Ishihara_2004_J.Hum.Genet_49_302
Author(s) : Ishihara M , Iwasaki T , Nagano M , Ishii J , Takano M , Kujiraoka T , Tsuji M , Hattori H , Emi M
Ref : J Hum Genet , 49 :302 , 2004
Abstract : Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor (PAF) acetylhydrolase (PAF-AH), is a member of the serine-dependent class of A2 phospholipases that hydrolyze sn2-ester bonds of fragmented or oxidized phospholipids at sites where atherosclerotic plaques are forming. Most circulating Lp-PLA2 is bound to low-density lipoprotein (LDL) particles in plasma and the rest to high-density lipoprotein (HDL). Deficiency of Lp-PLA2 is a predisposing factor for cardiovascular diseases in the Japanese population. We describe here two novel mutations of the gene encoding Lp-PLA2, InsA191 and I317N in Japanese subjects. The first patient, with partial Lp-PLA2 deficiency, was heterozygous for the InsA191 mutation; macrophages from this patient secreted only half the normal amount of Lp-PLA2 in vitro. The other patient, who showed complete Lp-PLA2 deficiency, was a compound heterozygote for the novel I317N mutation and a common V279F mutation; macrophages from that patient failed to secrete any Lp-PLA2. Measurement of Lp-PLA2 mass, activity and Western blotting verified impaired production and secretion of the enzyme after transfection of mutant construct into COS-7 cells. These results indicated that both novel mutants, InsA191 and I317N, impair function of the Lp-PLA2 gene.
ESTHER : Ishihara_2004_J.Hum.Genet_49_302
PubMedSearch : Ishihara_2004_J.Hum.Genet_49_302
PubMedID: 15148590
Gene_locus related to this paper: human-PLA2G7

Title : Inhibition of acetylcholinesterase activity by essential oil from Citrus paradisi - Miyazawa_2001_Nat.Prod.Lett_15_205
Author(s) : Miyazawa M , Tougo H , Ishihara M
Ref : Nat Prod Lett , 15 :205 , 2001
Abstract : Inhibition of acetylcholinesterase (AChE) activity by essential oils of Citrus paradisi (grapefruit pink in USA) was studied. Inhibition of AChE was measured by the colorimetric method. Nootkatone and auraptene were isolated from C. paradisi oil and showed 17-24% inhibition of AChE activity at the concentration of 1.62 microg/mL.
ESTHER : Miyazawa_2001_Nat.Prod.Lett_15_205
PubMedSearch : Miyazawa_2001_Nat.Prod.Lett_15_205
PubMedID: 11858553